Nanobody works against all SARS-CoV-2 variants of concern in animal model
Researchers based in Belgium have developed a new antibody drug that is highly successful at neutralizing coronavirus disease 2019 (COVID-19) in Syrian hamsters. The new biologic was administered to the rodents and was found to be equally successful at neutralizing the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain, and also the new mutant variants, such as the South African and UK strains.
A pre-print version of the research paper is available to read in full on the
Antibody immunity
Vaccines represent potent tools for combatting diseases, however, they are limited in some regards. Immunity may be short-lived or less effective in old age groups. Limited vaccine availability in many countries, vaccine hesitancy, are other factors of which the impact is currently uncertain.